Wednesday, 08 Apr 2020

You are here

Steroid-Sparing Effect of Tocilizumab in Refractory Takayasu Arteritis

A controlled clinical trial has shown that giving the IL-6 receptor antibody, tocilizumab (TCZ), to  patients with Takayasu arteritis (TAK) results in clinical efficacy and has a steroid sparing efffect.

A total of 36 TAK patients were enrolled in a randomized, double-blind, placebo-controlled study (TAKT - Takayasu arteritis Treated with Tocilizumab). after which they were given open-label, weekly s.c. tocilizumab 162 mg for up to 96 weeks or longer.  Glucocorticoid tapering was performed at the investigators’ discretion.

A total of 28 patients received open-label tocilizumab for 96 weeks.

The median glucocorticoid dose was 0.223 mg/kg/day at study entry; 0.131 mg/kg/day after 48 weeks; and 0.105 mg/kg/day after 96 weeks.

Overall, 46.4% of patients reduced their dose to <0.1 mg/kg/day, which was less than half the dose administered at relapse before study entry

Using imaging studies patients’ disease either was improved (17.9%) or stable (67.9%) after 96 weeks.

No unexpected safety issues were reported.

These results provide evidence of a steroid-sparing effect when TCZ is used in Takayasu arteritis patients.
 
Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

In Lupus, Keep BP Below 130/80

Blood pressure should be maintained at a level below 130/80 mm Hg in all patients with lupus to lessen their likelihood of atherosclerotic vascular events, Canadian researchers asserted.

In Vasculitis, Beware of Infection

Risks of infection were strikingly high among patients with antineutrophil cytoplasmic antibody-associated (ANCA) vasculitis, which may relate to both the disease and its treatment, Scottish researchers found.

Malignancies with Giant Cell Arteritis

The Journal of Rheumatology reports the findings of a Swedish population-based cohort study of biopsy-proven giant cell arteritis (GCA) patients showing that the overall risk for cancer was not increased; yet there appears to be an increased risk for leukemia and a decreased risk for breast and upper gastrointestinal tract cancers.   

Hospitalized GPA - Higher morbidity, Mortality and Cost

Rheumatology reports on a study of patients with granulomatosis with polyangiitis (GPA) showing worse outcomes and higher costs when hospitalized with GPA.

GPA patients were identified from the Nationwide Inpatient Sample (NIS) and were compared to those without GPA with regard to demographics, procedures, length of stay, mortality, morbidity and total hospitalization charges (between 2005–2014).

Don't Blame the Weather in Sjogren's

Seasonal variations in symptoms -- commonly reported by patients with rheumatic diseases -- were not observed in a large cohort of patients with primary Sjogren's syndrome, French investigators found.